UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 7, 2020

KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-36225**	**46-1160142**
(State or other jurisdiction of incorporation or organization)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

1555 Bayshore Highway, Suite 200, Burlingame, California 94010
(Address of principal executive offices) (Zip Code)

(650) 701-7901
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.0001 par value	KIN	The NASDAQ Stock Market LLC
Preferred Stock Purchase Rights	KIN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.

On October 7, 2020, Kindred Biosciences, Inc. (the "Company") and its wholly-owned subsidiary, Centaur Biopharmaceutical, Inc. ("Centaur"), issued respective press releases announcing the Company has expanded its agreement with Vaxart, Inc. ("Vaxart") for the manufacture of Vaxart's oral vaccine for COVID-19 and other vaccine candidates, with manufacturing services to be performed by Centaur. Copies of the press releases by the Company and Centaur are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release of Kindred Biosciences, Inc. issued on October 7, 2020
99.2	Press Release of Centaur Biopharmaceutical, Inc. issued on October 7, 2020
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KINDRED BIOSCIENCES, INC.

Date: October 7, 2020

By: /s/ Richard Chin
Richard Chin, M.D.
Chief Executive Officer

Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates

San Francisco, California (October 7, 2020) - Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.

"We are pleased to expand our partnership with Vaxart as they prepare to advance their novel COVID-19 vaccine candidate into the clinic," said KindredBio's Chief Executive Officer, Richard Chin, M.D. "This agreement further establishes us as a partner of choice for contract manufacturing, while supporting the development of our attractive pipeline of late stage assets."

Under the terms of the expanded agreement, the California plant will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors and the Kansas plant will be responsible for manufacturing at 2000L scale in its single use bioreactors.

"We are very pleased to have secured commercial scale bulk manufacturing with KindredBio, which has state-of-the-art capabilities in viral vector manufacturing. This is an essential next step in advancing our oral tablet vaccine candidate for COVID-19, which we believe could accelerate mass vaccination campaigns globally," said Vaxart's Chief Executive Officer, Andrei Floroiu.

About Kindred Biosciences

Kindred Biosciences is a biopharmaceutical company developing innovative biologics. The company has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio. For more information, please visit: www.kindredbio.com

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. For more information, please visit www.vaxart.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our

existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment and restructuring plans will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.

Contacts

For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438

For CDMO services:
Russell Harris
russell.harris@centaurbps.com

Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates

San Francisco, California (October 7, 2020) – Centaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced an expanded agreement between KindredBio and Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates.

Centaur is a full-service contract development and manufacturing organization that specializes in protein-based biologics and virus-based products. With state-of-the-art facilities in California and Kansas, Centaur's capabilities span cell line development, process development, analytical development, process characterization, clinical manufacturing, and commercial manufacturing including aseptic fill-and-finish.

"With this major contract, we are pleased to establish Centaur as a trusted partner for contract manufacturing," said Centaur's Chief Commercial Officer, Russell Harris. "We are excited to assist in this important project."

Under the terms of the expanded agreement, the California plant will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors and the Kansas plant will be responsible for manufacturing at 2000L scale in its single use bioreactors.

About Centaur Biopharmaceutical Services

Centaur Biopharmaceutical Services, Inc. is a full-service contract development and manufacturing organization that specializes in protein-based biologics. With state-of-the-art facilities in California and Kansas, Centaur's capabilities span production and process development, analytical development and process characterization. The team is experienced in cGMP biologics development, manufacturing, and aseptic fill-and-finish.

For more information, please visit: www.centaurbps.com/ or email info@centaurbps.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of KindredBio's current and future product candidates, and statements regarding anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: KindredBio's limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from KindredBio's products and product candidates for the foreseeable future; the likelihood that revenue will vary from quarter to quarter; KindredBio's potential inability to obtain any necessary additional financing; KindredBio's substantial dependence on the success of its products and lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; KindedBio's potential inability to obtain regulatory approval for existing or future product candidates; dependence on third parties to conduct some of KindredBio's development activities; dependence upon third-party manufacturers for supplies of products and product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on KindredBio's business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding product candidates; KindredBio's potential failure to attract and retain senior management and key scientific personnel; uncertainty about KindredBio's ability to

enter into satisfactory agreements with third-party licensees of its biologic products or to develop a satisfactory sales organization for its equine small molecule products; KindredBio's significant costs of operating as a public company; potential cyber-attacks on KindredBio's information technology systems or on its third-party providers' information technology systems, which could disrupt operations; KindredBio's potential inability to repay the secured indebtedness that it has incurred from third-party lenders, and the restrictions on business activities that are contained in KindredBio's loan agreement with these lenders; the risk that KindredBio's 2020 strategic realignment and restructuring plans will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that KindredBio will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; the potential inability to obtain and maintain patent protection and other intellectual property protection for KindredBio's products and product candidates; potential claims by third parties alleging infringement of their patents and other intellectual property rights; KindredBio's potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of KindredBio's stock price; and the significant control over KindredBio's business by its principal stockholders and management.

For a further description of these risks and other risks that KindredBio faces, please see the risk factors described in KindredBio's filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption "Risk Factors" in KindredBio's Annual Report on Form 10-K and any subsequent updates that may be contained in KindredBio's Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in KindredBio's filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and KindredBio undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts

Russell Harris
russell.harris@centaurbps.com